Abvc Biopharma (ABVC) Other Non-Current Liabilities (2019 - 2026)

Abvc Biopharma (ABVC) has reported Other Non-Current Liabilities for 8 consecutive years, with $31167.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Non-Current Liabilities fell 25.22% year-over-year to $31167.0; the trailing twelve-month figure through Jun 2026 stood at $31167.0 (down 25.22% YoY), and the FY2024 full-year result was $21680.0, changed 0.0% from the prior year.
• Other Non-Current Liabilities declined to $31167.0 in Q2 2026 per ABVC's latest filing, from $35404.0 in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $41680.0 in Q2 2025 and bottomed at $5680.0 in Q2 2023.
• Historically, Other Non-Current Liabilities has averaged $19249.4 across 5 years, with a median of $21680.0 in 2023.
• The sharpest annual moves came in 2023 and 2024: Other Non-Current Liabilities slumped 55.9% in 2023, then jumped 387.32% in 2024.
• Over 5 years, Other Non-Current Liabilities stood at $7980.0 in 2022, then jumped by 171.68% to $21680.0 in 2023, then changed by 0.0% to $21680.0 in 2024, then surged by 63.3% to $35404.0 in 2025, then declined by 11.97% to $31167.0 in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $31167.0, $35404.0, and $41680.0 for Q2 2026, Q3 2025, and Q2 2025 respectively.